StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
96
This month
2
This year
5
Publishing Date
2023 - 06 - 29
3
2023 - 06 - 16
3
2023 - 05 - 23
2
2023 - 04 - 20
1
2023 - 04 - 19
1
2023 - 03 - 09
1
2022 - 12 - 08
1
2022 - 11 - 23
1
2022 - 11 - 04
1
2022 - 09 - 27
1
2022 - 09 - 21
1
2022 - 08 - 23
1
2022 - 08 - 01
1
2022 - 07 - 07
1
2022 - 06 - 22
1
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 05 - 26
1
2022 - 05 - 17
1
2022 - 05 - 05
1
2022 - 04 - 29
1
2022 - 03 - 21
1
2022 - 03 - 17
2
2022 - 03 - 09
1
2022 - 03 - 04
1
2022 - 02 - 18
1
2022 - 01 - 26
1
2022 - 01 - 18
1
2022 - 01 - 06
1
2022 - 01 - 05
1
2021 - 12 - 28
1
2021 - 12 - 16
1
2021 - 11 - 29
1
2021 - 11 - 15
1
2021 - 11 - 03
1
2021 - 10 - 20
1
2021 - 10 - 18
1
2021 - 10 - 13
1
2021 - 10 - 07
2
2021 - 09 - 15
1
2021 - 08 - 11
1
2021 - 08 - 06
1
2021 - 07 - 29
1
2021 - 07 - 19
1
2021 - 07 - 12
1
2021 - 06 - 28
2
2021 - 06 - 18
1
2021 - 06 - 14
1
2021 - 05 - 24
1
2021 - 04 - 28
1
2021 - 04 - 27
1
2021 - 04 - 23
1
2021 - 04 - 22
1
2021 - 04 - 19
1
2021 - 04 - 09
1
2021 - 04 - 05
1
2021 - 03 - 24
1
2021 - 03 - 15
2
2021 - 01 - 19
1
2021 - 01 - 04
1
Sector
Commercial services
1
Communications
2
Consumer non-durables
2
Electronic technology
3
Health technology
57
Industrial services
1
Manufacturing
7
N/a
7
Process industries
1
Producer manufacturing
14
Retail trade
3
Tags
500
1
5g
1
Ab-101
1
Adhd
3
Alliances
2
Als
4
Biotechnology
2
Bnc210
2
Brazil
2
Cancer
4
Cell
2
Clearance
2
Clinical trials
2
Clinical-trials-phase-i
2
Clinical-trials-phase-ii
9
Clinical-trials-phase-iii
8
Communications
2
Conference
3
Covid
5
Covid-19
2
Disease
5
Drug
3
Energy
2
Europe
6
Fda
3
Financial results
3
Growth
3
Iot
4
Kidney
3
Lancet
2
Life
2
Melanoma
2
N/a
61
Obesity
2
Pancreatic
2
Pharma
6
Phase 1
2
Phase 2
9
Phase 2b
4
Phase 3
5
Positive
10
Preclinical
2
Presentation
2
Product-news
3
Publication
2
Report
2
Research
8
Results
20
Risk
2
Study
7
Test
2
Therapeutics
7
Therapy
4
Topline
3
Treatment
5
Trial
81
Trials
3
Tumors
4
Update
2
Vaccine
3
Entities
Abb ltd
4
Abivax s.a.
1
Achieve life sciences, inc.
1
Adc therapeutics sa
1
Affimed n.v.
1
Akili inc
1
Alx oncology holdings inc.
1
Aptevo therapeutics inc.
1
Argenx se
1
Arrival
1
Astrazeneca plc
2
Aurinia pharmaceuticals inc
1
Baker hughes company
1
Belite bio, inc
1
Biocardia, inc.
1
Bionomics limited/fi
2
Biontech se
1
Biophytis - adr
1
Bioxcel therapeutics, inc.
1
Brainstorm cell therapeutics inc.
2
Bristol-myers squibb company
1
Ceragon networks ltd.
1
Cingulate inc.
1
Clearmind medicine inc.
1
Cnh industrial n.v.
7
Daikin industries ltd
1
Dow inc.
1
Durect corporation
1
Dynavax technologies corporation
1
Eli lilly and company
3
Evotec se
1
Evotec se - adr
1
Global industrial co
2
Hologic, inc.
1
Honeywell international inc.
4
Hyzon motors inc - class a
1
I-mab
1
Icon plc
1
Ideaya biosciences, inc.
4
Immuron limited
1
Innate pharma s.a.
3
Innate pharma sa
3
Innospec inc.
1
Johnson & johnson
3
Johnson controls international plc
3
Kering
2
Keros therapeutics, inc.
1
Kodiak sciences inc
1
Koninklijke philips n.v.
2
Kymera therapeutics, inc.
1
Mainz biomed b.v.
1
Masimo corporation
1
Medicinova, inc.
1
Novartis ag
2
Novavax, inc.
2
Novo nordisk a/s
5
Orange
2
Pfizer, inc.
2
Sanofi
6
Verona pharma plc
2
Symbols
ABB
4
ABLZF
3
ABVX
1
ACHV
1
ADCT
1
AFMD
1
AKLI
1
ALXO
1
APVO
1
ARGX
1
ARVL
1
AUPH
1
AZN
2
BCDA
1
BCLI
2
BKR
1
BLTE
1
BMY
1
BNOX
2
BNTX
1
BPTS
1
BTAI
1
CING
1
CMND
1
CNHI
7
CRNT
1
DKILF
1
DKILY
1
DOW
1
DRRX
1
DVAX
1
EVO
1
EVOTF
1
FNCTF
2
GIC
2
HOLX
1
HON
4
HYZN
1
ICLR
1
IDYA
4
IMAB
1
IMRN
1
IOSP
1
IPHA
3
IPHYF
3
JCI
3
JNJ
3
KOD
1
KROS
1
LLY
3
NVAX
2
NVO
5
NVS
2
PFE
2
PHG
2
PPRUF
2
PPRUY
2
SNY
6
SNYNF
3
VRNA
2
Exchanges
Nasdaq
70
Nyse
39
Crawled Date
2023 - 06 - 29
3
2023 - 06 - 16
3
2023 - 05 - 23
2
2023 - 04 - 26
1
2023 - 04 - 20
1
2023 - 04 - 19
1
2023 - 03 - 09
1
2022 - 12 - 08
1
2022 - 11 - 23
1
2022 - 11 - 04
1
2022 - 09 - 27
1
2022 - 09 - 21
1
2022 - 08 - 23
1
2022 - 08 - 01
1
2022 - 07 - 07
1
2022 - 06 - 22
1
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 05 - 26
1
2022 - 05 - 17
1
2022 - 05 - 05
1
2022 - 04 - 29
1
2022 - 03 - 21
1
2022 - 03 - 17
2
2022 - 03 - 09
1
2022 - 03 - 04
1
2022 - 02 - 18
1
2022 - 01 - 26
1
2022 - 01 - 18
1
2022 - 01 - 06
2
2021 - 12 - 28
1
2021 - 12 - 16
1
2021 - 11 - 29
1
2021 - 11 - 15
1
2021 - 11 - 03
1
2021 - 10 - 20
1
2021 - 10 - 18
1
2021 - 10 - 13
1
2021 - 10 - 07
2
2021 - 09 - 15
1
2021 - 08 - 11
1
2021 - 08 - 06
1
2021 - 07 - 29
1
2021 - 07 - 19
1
2021 - 07 - 12
1
2021 - 06 - 28
2
2021 - 06 - 18
1
2021 - 06 - 14
1
2021 - 05 - 24
1
2021 - 04 - 28
1
2021 - 04 - 27
1
2021 - 04 - 23
1
2021 - 04 - 22
1
2021 - 04 - 19
1
2021 - 04 - 09
1
2021 - 04 - 05
1
2021 - 03 - 24
1
2021 - 03 - 15
2
2021 - 01 - 19
1
2021 - 01 - 04
1
Crawled Time
00:00
172
00:20
52
01:00
99
02:00
31
03:00
24
03:10
4
04:00
27
04:20
23
05:00
47
06:00
62
07:00
97
08:00
63
08:20
9
09:00
73
09:33
4
10:00
96
10:08
8
11:00
473
11:03
4
12:00
1151
12:01
13
12:03
20
12:07
4
12:15
135
12:20
210
12:30
178
12:39
4
13:00
904
13:01
16
13:03
15
13:05
6
13:07
5
13:15
103
13:20
200
13:30
196
13:35
7
14:00
710
14:01
10
14:03
6
14:04
4
14:15
58
14:20
107
14:30
114
15:00
439
15:15
35
15:20
49
15:30
92
16:00
258
16:20
61
17:00
264
18:00
199
19:00
190
20:00
263
20:20
53
21:00
332
22:00
329
22:01
6
22:08
6
22:10
5
23:00
221
Source
ir.auriniapharma.com
1
ocutx.gcs-web.com
1
revivapharma.com
1
www.biospace.com
35
www.ceragon.com
1
www.globenewswire.com
32
www.prnewswire.com
25
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
trial
crawled time :
10:00
save search
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Published:
2024-04-10
(Crawled : 10:00)
- prnewswire.com
BCLI
A
|
$0.5339
1.7%
1.67%
190K
|
Health Technology
|
-25.68%
|
O:
-20.14%
H:
0.0%
C:
0.0%
als
biomarker
publication
cell
trial
therapeutics
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published:
2024-04-09
(Crawled : 10:00)
- prnewswire.com
BCLI
A
|
$0.5339
1.7%
1.67%
190K
|
Health Technology
|
-17.91%
|
O:
10.45%
H:
0.0%
C:
0.0%
fda
als
cell
for
trial
therapeutics
agreement
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Published:
2024-03-21
(Crawled : 10:00)
- globenewswire.com
BNOX
|
$0.9232
-4.33%
25K
|
n/a
|
-8.78%
|
O:
2.75%
H:
3.74%
C:
-6.54%
bnc210
trial
results
Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial
Published:
2024-03-05
(Crawled : 10:00)
- globenewswire.com
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
-1.4%
|
O:
-1.33%
H:
0.46%
C:
-1.27%
disease
kidney
risk
trial
diabetes
flow
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Published:
2024-01-24
(Crawled : 10:00)
- biospace.com/
ABVX
|
$15.96
0.63%
0.63%
7.5K
|
n/a
|
33.08%
|
O:
-1.76%
H:
3.24%
C:
1.36%
active
review
trial
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Published:
2023-12-12
(Crawled : 10:00)
- globenewswire.com
ADCT
|
$4.78
-3.82%
0.0%
280K
|
Health Technology
|
378.0%
|
O:
1.0%
H:
2.97%
C:
1.98%
zynlonta
trial
therapeutics
results
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
Published:
2023-12-06
(Crawled : 10:00)
- biospace.com/
TEVA
|
$13.01
-0.68%
7.5M
|
Health Technology
|
29.32%
|
O:
0.1%
H:
1.09%
C:
-2.38%
ajovy
obesity
migraine
BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II
Published:
2023-10-11
(Crawled : 10:00)
- globenewswire.com
BCDA
P
|
$0.376
-2.56%
64K
|
Health Technology
|
-2.49%
|
O:
4.46%
H:
27.73%
C:
22.82%
cardiamp
trial
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
Published:
2023-10-03
(Crawled : 10:00)
- globenewswire.com
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
36.59%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALXO
M
|
$16.24
4.77%
4.56%
440K
|
Commercial Services
|
237.21%
|
O:
68.19%
H:
2.84%
C:
-7.17%
aspen-06
positive
cancer
treatment
trial
results
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published:
2023-09-28
(Crawled : 10:00)
- globenewswire.com
BNOX
|
$0.9232
-4.33%
25K
|
n/a
|
-3.55%
|
O:
480.71%
H:
12.06%
C:
-41.08%
bnc210
positive
topline
trial
results
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Published:
2023-09-25
(Crawled : 10:00)
- revivapharma.com
RVPH
|
$3.02
-1.31%
-1.32%
78K
|
|
-38.37%
|
O:
0.0%
H:
2.1%
C:
-1.84%
brilaroxazine
schizophrenia
trial
Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Published:
2023-09-11
(Crawled : 10:00)
- globenewswire.com
CING
|
$0.8787
-2.9%
19K
|
|
-92.47%
|
O:
-6.51%
H:
6.19%
C:
6.19%
adhd
trial
results
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
Published:
2023-08-16
(Crawled : 10:00)
- prnewswire.com
IDYA
|
News
|
$39.85
2.13%
2.08%
1.3M
|
Health Technology
|
55.54%
|
O:
0.43%
H:
2.99%
C:
-1.79%
melanoma
trial
phase 2
Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial
Published:
2023-08-08
(Crawled : 10:00)
- globenewswire.com
NVO
|
News
|
$126.16
-1.93%
-0.23%
3.1M
|
Health Technology
|
56.37%
|
O:
15.34%
H:
3.26%
C:
1.64%
obesity
risk
trial
cardiovascular
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published:
2023-07-27
(Crawled : 10:00)
- biospace.com/
AZN
|
News
|
$71.175
0.46%
0.46%
6.1M
|
Health Technology
|
4.03%
|
O:
0.42%
H:
0.55%
C:
-0.86%
enhertu
her2
tumors
trial
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
Published:
2023-07-24
(Crawled : 10:00)
- globenewswire.com
BLTE
|
$37.23
0.62%
0.62%
33K
|
n/a
|
113.34%
|
O:
0.17%
H:
7.09%
C:
4.0%
disease
global
trial
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
Published:
2023-07-03
(Crawled : 10:00)
- globenewswire.com
ZEAL
|
$17.59
1.21%
-4.21%
|
Health Technology
|
Email alert
Add to watchlist
zp8396
pharma
positive
trial
results
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
Published:
2023-06-29
(Crawled : 10:00)
- globenewswire.com
MNOV
|
$1.33
-3.73%
8K
|
Health Technology
|
-40.0%
|
O:
0.89%
H:
1.76%
C:
0.88%
mn-166
alcohol
presentation
research
meeting
trial
results
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation
Published:
2023-06-29
(Crawled : 10:00)
- globenewswire.com
BTAI
|
News
|
$2.7
-9.09%
-10.0%
880K
|
Health Technology
|
-84.66%
|
O:
-51.1%
H:
9.49%
C:
-26.04%
bxcl501
alzheimer’s
positive
treatment
topline
trial
therapeutics
results
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
Published:
2023-06-29
(Crawled : 10:00)
- biospace.com/
EVO
|
$5.22
-31.77%
-46.55%
1.5M
|
Manufacturing
|
-54.0%
|
O:
-2.29%
H:
0.54%
C:
0.45%
disease
kidney
payment
milestone
study
← Previous
1
2
3
4
5
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.